Of interest is that, in the K562, a CML cell line, there was no statistically significant decline in the levels of NF-κB p65, even with the highest dose of SMCAF, i.e., 0.4 mg/mL used (Figure 4). The gene discussed is NFKB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.